Clinical Trial Update: Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment [Phase 4]

View source ↗

Summary

Phase 4 trial updating prevention of recurrence after kidney transplantation in IgA nephropathy comparing ATG-F versus Basiliximab induction immunosuppressive t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glomerulonephritis
• Iga Nephropathy

Drugs mentioned

• ATG-F (anti-thymocyte globulin fragment F)
• Basiliximab (basiliximab)

Snippet

Sponsor: Centre Hospitalier Universitaire de Saint Etienne | Conditions: Glomerulonephritis, IgAN | Phase 4 | Status: TERMINATED